Literature DB >> 2431313

Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.

C A Koller, D M Miller.   

Abstract

We observed a dramatic improvement in the peripheral blood counts of a patient in the myeloid blast phase of chronic granulocytic leukemia after plicamycin (mithramycin) therapy of concurrent hypercalcemia. We then treated eight additional patients in the blast phase of chronic granulocytic leukemia with a combination of alternate-day plicamycin and daily hydroxyurea. All six patients with myeloid morphology at the time of blast crisis responded with a return to a chronic phase without an intervening pancytopenic period. Of three patients with lymphoid morphology at the time of treatment, only one responded (this patient had recently relapsed and converted from myeloid to lymphoid morphology). Another patient with nonmyeloid, nonlymphoid blast morphology also did not respond. Continual therapy with the two-drug combination appeared to be necessary, since early relapses were seen in responding patients whose therapy was interrupted. These data are preliminary and will need further confirmation, but they suggest that the combination of alternate-day plicamycin and daily hydroxyurea may be effective in the myeloid blast phase of chronic granulocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2431313     DOI: 10.1056/NEJM198612043152301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  20 in total

1.  Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.

Authors:  L H Trümper; A D Ho; W Hunstein; H van der Lelie; R Goudsmit
Journal:  Blut       Date:  1989-02

2.  The development of new anticancer drugs.

Authors:  F M Arcamone
Journal:  World J Microbiol Biotechnol       Date:  1992-12       Impact factor: 3.312

Review 3.  Chronic myelogenous leukemia of childhood.

Authors:  K L Saving
Journal:  Indian J Pediatr       Date:  1987 Nov-Dec       Impact factor: 1.967

4.  HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.

Authors:  Paolo Strati; Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Sergej Konoplev; Jeffrey L Jorgensen; Raja Luthra; Lynne Abruzzo; Elias Jabbour; Alfonso Quintas-Cardama; Gautam Borthakur; Stefan Faderl; Farhad Ravandi; Jorge Cortes
Journal:  Cancer       Date:  2013-10-22       Impact factor: 6.860

5.  Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia.

Authors:  E Archimbaud; J Troncy; C Sebban; D Guyotat; Y Devaux; M French; M Moriceau; J J Viala; D Fiere
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.

Authors:  Janina Seznec; Björn Silkenstedt; Ulrike Naumann
Journal:  J Neurooncol       Date:  2010-06-17       Impact factor: 4.130

7.  Mithramycin blocks protein binding and function of the SV40 early promoter.

Authors:  R Ray; R C Snyder; S Thomas; C A Koller; D M Miller
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

8.  Semi-synthetic mithramycin SA derivatives with improved anticancer activity.

Authors:  Daniel Scott; Jhong-Min Chen; Younsoo Bae; Jürgen Rohr
Journal:  Chem Biol Drug Des       Date:  2013-04-04       Impact factor: 2.817

9.  Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients.

Authors:  B Anger; F Carbonell; I Braunger; B Heinze; W Gutensohn; E Thiel; H Heimpel
Journal:  Blut       Date:  1988-09

Review 10.  Accelerated and blastic phase of chronic myeloid leukemia.

Authors:  J P Dutcher; P H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2000-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.